Kyverna Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Kyverna Therapeutics, Inc. (KYTX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $1.55 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-26
- Kyverna Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $1.55M, a 13.26% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $1.37M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-12-31 | $1.55M 10-K · filed 2026-03-26 |
| 2024-12-31 | $1.37M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |